This inventor holds 1 USPTO granted patent. Top assignee: The Schepens Eye Research Institute, Inc.. Active years: 2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003
Title: The Innovative Contributions of Tadashi Senoo
Introduction
Tadashi Senoo is a notable inventor based in Tochigi, Japan. He has made significant contributions to the field of ophthalmology, particularly in the area of corneal cell research. His work focuses on enhancing the proliferation of adult corneal endothelial cells, which is crucial for maintaining corneal health and transparency.
Latest Patents
Tadashi Senoo holds a patent for a method that promotes the proliferation of adult corneal endothelial cells. This innovative method involves incubating corneal endothelium in a mitogen-containing medium, followed by treatment with an agent that interrupts cell-cell contacts in the adult corneal endothelial cells. The preferred agent for this process is a calcium chelator, which facilitates further incubation in the mitogen-containing medium as needed. This patent represents a significant advancement in regenerative medicine for the eye.
Career Highlights
Senoo is affiliated with the Schepens Eye Research Institute, Inc., where he conducts his research. His work has been instrumental in developing new techniques for cell proliferation, which can potentially lead to improved treatments for corneal diseases.
Collaborations
Throughout his career, Tadashi Senoo has collaborated with esteemed colleagues, including Nancy C. Joyce and Ko-Hua Chen. These collaborations have enriched his research and contributed to the advancement of knowledge in the field of eye health.
Conclusion
Tadashi Senoo's innovative work in promoting the proliferation of adult corneal endothelial cells showcases his dedication to advancing ophthalmic research. His contributions have the potential to significantly impact the treatment of corneal conditions and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
